EcoDrugPlus

Adrenoceptor Alpha 1b

Ensembl ID : ENSBTAG00000040253
Gene Symbol: ADRA1B
9 Enzyme and pathways 5 Cross references
277 Possible Orthologues:

Adrenoceptor Alpha 1d

Ensembl ID : ENSBTAG00000019504
Gene Symbol: ADRA1D
9 Enzyme and pathways 5 Cross references
208 Possible Orthologues:

Adrenoceptor Alpha 2a

Ensembl ID : ENSBTAG00000039292
Gene Symbol: ADRA2A
19 Enzyme and pathways 5 Cross references
239 Possible Orthologues:

Adrenoceptor Alpha 2b

Ensembl ID : ENSBTAG00000009510
Gene Symbol: ADRA2B
13 Enzyme and pathways 5 Cross references
232 Possible Orthologues:

Adrenoceptor Alpha 2c

Ensembl ID : ENSBTAG00000045994
Gene Symbol: ADRA2C
19 Enzyme and pathways 5 Cross references
238 Possible Orthologues:

Adrenoceptor Beta 1

Ensembl ID : ENSBTAG00000001242
Gene Symbol: ADRB1
8 Enzyme and pathways 5 Cross references
174 Possible Orthologues:

Adrenoceptor Beta 2

Ensembl ID : ENSBTAG00000002144
Gene Symbol: ADRB2
16 Enzyme and pathways 5 Cross references
276 Possible Orthologues:

Adrenoceptor Beta 3

Ensembl ID : ENSBTAG00000017981
Gene Symbol: ADRB3
8 Enzyme and pathways 5 Cross references
231 Possible Orthologues:

Advanced Glycosylation End-Product Specific Receptor

Ensembl ID : ENSBTAG00000014420
Gene Symbol: AGER
26 Enzyme and pathways 5 Cross references
182 Possible Orthologues:

Alcohol Dehydrogenase 5 (Class Iii), Chi Polypeptide

Ensembl ID : ENSBTAG00000016007
Gene Symbol: ADH5
4 Enzyme and pathways 4 Cross references
418 Possible Orthologues:

Aldo-Keto Reductase Family 1, Member B1 (Aldose Reductase)

Ensembl ID : ENSBTAG00000009902
Gene Symbol: AKR1B1
8 Enzyme and pathways 4 Cross references
413 Possible Orthologues:

Alpha Glucosidase

Ensembl ID : ENSBTAG00000016021
Gene Symbol: GAA
7 Enzyme and pathways 5 Cross references
245 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).